Douglas R. Carlson, Chief Financial and Business Officer of Avalyn Pharma Inc. (NASDAQ:AVLN), filed a Form 4 on November 19, 2026, disclosing option exercises and open-market share sales on November 17, 2026, executed under a Rule 10b5-1 trading plan.

Key Highlights

  • Option exercise: Carlson exercised stock options covering 14,875 shares of common stock at an exercise price of $4.62 per share on November 17, 2026.
  • Three tranches sold: He disposed of 11,527 shares at a weighted average price of $27.781, 3,093 shares at a weighted average price of $28.2246, and 255 shares at a weighted average price of $29.2267.
  • Post-transaction ownership: Following all reported transactions, Carlson held 0 shares of common stock directly and 255,623 derivative securities (stock options) directly.
  • 10b5-1 plan: All transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2026, according to the filing.
  • Option vesting schedule: The filing states that 25% of the underlying option shares vested on May 1, 2025, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter, subject to continued service.
  • Option expiration: The exercised stock option carries an expiration date of June 10, 2034.

Carlson's November 17 Option Exercise and Share Disposals at Avalyn Pharma

According to the Form 4 filed with the SEC on November 19, 2026, Douglas R. Carlson, identified in the filing as Chief Financial and Business Officer of Avalyn Pharma Inc. (NASDAQ:AVLN), exercised stock options for 14,875 shares of common stock at $4.62 per share on November 17, 2026. The filing records the exercise under transaction code "M" and notes that the acquisition brought his direct common stock position to 14,875 shares at that point in the sequence.

Carlson then disposed of all 14,875 shares across three same-day sale transactions, each coded "S." The first sale covered 11,527 shares at a weighted average price of $27.781, with individual transaction prices ranging from $27.06 to $28.05. The second covered 3,093 shares at a weighted average price of $28.2246, with prices ranging from $28.06 to $29.04. The third covered the remaining 255 shares at a weighted average price of $29.2267, with prices ranging from $29.09 to $29.25. After these disposals, the filing reports his direct common stock holdings at 0 shares.

The filing states that all transactions were made pursuant to a Rule 10b5-1 trading plan that Carlson adopted on July 30, 2026. His remaining beneficial ownership consists of 255,623 stock options (right to buy) held directly, with an exercise price of $4.62 and an expiration date of June 10, 2034. The filing notes that Carlson undertakes to provide full detail on shares sold at each separate price upon request by the issuer, any security holder, or SEC staff.

What Was Disclosed

Carlson disclosed the exercise of 14,875 stock options at $4.62 per share and the same-day sale of all resulting common shares across three price tranches on November 17, 2026, all under a pre-established Rule 10b5-1 plan, leaving him with no direct common stock holdings.